• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ERT partners with GE Healthcare

ERT partners with GE Healthcare

April 11, 2014
CenterWatch Staff

ERT, a global solution provider for high-quality patient safety and efficacy endpoint data collection, has entered into an agreement with GE Healthcare that enables ERT to introduce the QT Guard Plus Analysis System to the clinical trial industry as part of its centralized cardiac safety solutions. 

The QT Guard Plus Analysis System enables biopharmaceutical companies to analyze detailed morphology of the ECG T-wave, which can help identify new drugs that have an effect on QT. ERT has incorporated this algorithm tool into its EXPERT platform.

During clinical development, biopharmaceutical companies are required to conduct cardiac safety studies to evaluate if new drugs can trigger a potentially fatal disordered heart beat known as Torsades de Pointes (TdP).  Since prolongation of the QT interval on the surface ECG provides evidence of the common mechanism by which drugs produce TdP, thorough QT/QTc (TQT) studies have become the industry standard for meeting this requirement.

However, measurement of the QT interval can be difficult and has led to the termination of promising drugs that showed some degree of QT prolongation in early studies, but otherwise did not demonstrate evidence of proarrhythmia, a harmful effect.

The QT Guard Plus Algorithm identifies and quantifies characteristic changes in the shape of the T-wave found in drugs that produce TdP. The ability to perform this quantitative analysis can help to distinguish between drugs which are proarrhythmic and those which are not.

“We believe that T-wave morphology analysis may help to better assess the arrhythmogenic potential of drugs which have a small or equivocal QT effect, and may be a very useful adjunct to traditional QT studies,” said Dr. Robert Kleiman, ERT’s chief medical officer.  “The initial peer reviewed literature is very promising that T-wave morphology analysis may help improve cardiac safety while preserving the drug development pipeline.”

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing